-
Acelyrin Inc. NasdaqGS:SLRN Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Location: 4149 Liberty Canyon Road, Agoura Hills, CA, 91301, United States | Website: https://www.acelyrin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-176.4M
Cash
410.6M
Avg Qtr Burn
-71.39M
Short % of Float
5.22%
Insider Ownership
7.14%
Institutional Own.
92.06%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lonigutamab Details Thyroid Eye Disease , Eye disease | Phase 3 Initiation | |
Izokibep Details Axial spondyloarthritis | Failed Discontinued | |
Izokibep Details Psoriatic arthritis | Failed Discontinued | |
Izokibep Details Uveitis , Eye disease | Failed Discontinued | |
SLRN-517 Details Allergy, Inflammatory disease, KIT/Mast cell diseases | Failed Discontinued | |
Izokibep Details Hidradenitis suppurativa | Failed Discontinued |